Adagene (ADAG) - צמיחת רווחים בשנה הנוכחית

Adagene is accelerating the launch of safe antibodies through partnerships with global oncology drug developers. The year-over-year relative change in EPS reflects current trends, with the metric holding around -80.80. Stable demand for cancer therapy offsets economic cycles, while the confidence of pharma behemoths in the company's AI platform guarantees it a strong market position.

For Adagene (ADAG), the annual net income per share trend on the GURU.Markets platform reflects the actual scaling efficiency of the SAFEbody AI platform. This metric measures the percentage change in EPS by comparing current results with the same period last year. This metric reveals the sustainability of corporate growth while filtering out market noise. For the immunopharmaceutical business, this serves as an indicator of B2B licensing success. The positive trend confirms the capitalization of a technological advantage in oncology.